# US 2024/0197761 A1 · Fucosylation and immune modulation in cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197761 A1
- Document ID: US20240197761A1
- Status: Published application
- Kind: A1
- Application number: 18/555,582
- Filed: 2022-04-18
- Published: 2024-06-20
- Earliest claimed: 2021-04-16
- Applicants: H. Lee Moffitt Cancer Center and Research Institute, Inc.
- Inventors: Eric K. LE-LAU
- Web page: https://patentgrep.com/patent/US20240197761A1

## CPC

- A61K 31/7004: Monosaccharides having only carbon, hydrogen and oxygen atoms
- A23L 33/125: containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates (indigestible substances A23L33/21)
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are methods for treating infectious diseases and cancers comprising administering to a subject a L-fucose.

## Claims

### Claim 1

A method of treating a treating, inhibiting, decreasing, reducing, ameliorating, and/or preventing an infectious disease or highly immunosuppressive cancer and/or metastasis in a subject comprising administering to the subject an agent that increases the amount of fucosylation on myeloid derived suppressor cells (MDSC) and MDSC-like cells.

### Claim 2 (depends on 1)

The method of treating a treating, inhibiting, decreasing, reducing, ameliorating, and/or preventing an infectious disease or highly immunosuppressive cancer and/or metastasis in a subject of claim 1, wherein the agent that increases fucosylation comprises L-fucose, D-fucose, fucose-1-phosphate, or GDP-L-fucose.

### Claim 3 (depends on 1)

The method of treating a treating, inhibiting, decreasing, reducing, ameliorating, and/or preventing an infectious disease or highly immunosuppressive cancer and/or metastasis in a subject of claim 1, wherein the agent that modulates fucosylation is administered orally.

### Claim 4 (depends on 1)

The method of treating a treating, inhibiting, decreasing, reducing, ameliorating, and/or preventing an infectious disease or highly immunosuppressive cancer and/or metastasis in a subject of claim 1 further comprising administering to the subject an immune checkpoint blockade inhibitor.

### Claim 5 (depends on 4)

The method of treating a treating, inhibiting, decreasing, reducing, ameliorating, and/or preventing an infectious disease or highly immunosuppressive cancer and/or metastasis in a subject of claim 4, wherein the immune checkpoint blockade inhibitor is selected from the group consisting of the PD-1 inhibitors lambrolizumab, OPDIVO® (Nivolumab), KEYTRUDA® (pembrolizumab), and/or pidilizumab; the PD-L1 inhibitors BMS-936559, TECENTRIQ® (Atezolizumab), IMFINZI® (Durvalumab), and/or BAVENCIO® (Avelumab); and/or the CTLA-4 inhibitor YERVOY (ipilimumab).

### Claim 6 (depends on 1)

The method of treating a treating, inhibiting, decreasing, reducing, ameliorating, and/or preventing an infectious disease or highly immunosuppressive cancer and/or metastasis in a subject of claim 1, wherein the fucose is administered before and/or during administration of the immune checkpoint inhibitor.

### Claim 7 (depends on 1)

The method of treating a treating, inhibiting, decreasing, reducing, ameliorating, and/or preventing an infectious disease or highly immunosuppressive cancer and/or metastasis in a subject of claim 1 further comprising administering to the subject an adoptive cell therapy.

### Claim 8 (depends on 7)

The method of treating a treating, inhibiting, decreasing, reducing, ameliorating, and/or preventing an infectious disease or highly immunosuppressive cancer and/or metastasis in a subject of claim 7, wherein the adoptive cell therapy comprises the transfer of tumor infiltrating lymphocytes (TILs), tumor infiltrating NK cells (TINKs), marrow infiltrating lymphocytes (MILs), chimeric antigen receptor (CAR) T cells, and/or CAR NK cells.

### Claim 9 (depends on 1)

The method of treating a treating, inhibiting, decreasing, reducing, ameliorating, and/or preventing an infectious disease or highly immunosuppressive cancer and/or metastasis in a subject of claim 1, wherein the infectious disease comprises an infection from a virus selected from the group of viruses consisting of Herpes Simplex virus-1, Herpes Simplex virus-2, Varicella-Zoster virus, Epstein-Barr virus, Cytomegalovirus, Human Herpes virus-6, Variola virus, Vesicular stomatitis virus, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, Hepatitis D virus, Hepatitis E virus, Rhinovirus, Coronavirus (including, but not limited to avian coronavirus (IBV), porcine coronavirus HKU15 (PorCoV HKU15), Porcine epidemic diarrhea virus (PEDV), HCoV-229E, HCoV-OC43, HCoV-HKU1, HCoV-NL63, SARS-CoV, SARS-CoV-2, or MERS-CoV), Influenza virus A, Influenza virus B, Measles virus, Polyomavirus, Human Papillomavirus, Respiratory syncytial virus, Adenovirus, Coxsackie virus, Chikungunya virus, Dengue virus, Mumps virus, Poliovirus, Rabies virus, Rous sarcoma virus, Reovirus, Yellow fever virus, Ebola virus, Marburg virus, Lassa fever virus, Eastern Equine Encephalitis virus, Japanese Encephalitis virus, St. Louis Encephalitis virus, Murray Valley fever virus, West Nile virus, Rift Valley fever virus, Rotavirus A, Rotavirus B, Rotavirus C, Sindbis virus, Simian Immunodeficiency virus, Human T-cell Leukemia virus type-1, Hantavirus, Rubella virus, Simian Immunodeficiency virus, Human Immunodeficiency virus type-1, and Human Immunodeficiency virus type-2.

### Claim 10 (depends on 1)

The method of treating a treating, inhibiting, decreasing, reducing, ameliorating, and/or preventing an infectious disease or highly immunosuppressive cancer and/or metastasis in a subject of claim 1, wherein the infectious disease comprises an infection from a bacteria selected from the group of bacteria consisting of Mycobacterium tuberculosis, Mycobacterium bovis, Mycobacterium bovis strain BCG, BCG substrains, Mycobacterium avium, Mycobacterium intracellular, Mycobacterium africanum, Mycobacterium kansasii, Mycobacterium marinum, Mycobacterium ulcerans, Mycobacterium avium subspecies paratuberculosis, Mycobacterium chimaera, Nocardia asteroides, other Nocardia species, Legionella pneumophila, other Legionella species, Acetinobacter baumanii, Salmonella typhi, Salmonella enterica, other Salmonella species, Shigella boydii, Shigella dysenteriae, Shigella sonnei, Shigella flexneri, other Shigella species, Yersinia pestis, Pasteurella haemolytica, Pasteurella multocida, other Pasteurella species, Actinobacillus pleuropneumoniae, Listeria monocytogenes, Listeria ivanovii, Brucella abortus, other Brucella species, Cowdria ruminantium, Borrelia burgdorferi, Bordetella avium, Bordetella pertussis, Bordetella bronchiseptica, Bordetella trematum, Bordetella hinzii, Bordetella pteri, Bordetella parapertussis, Bordetella ansorpii other Bordetella species, Burkholderia mallei, Burkholderia psuedomallei, Burkholderia cepacian, Chlamydia pneumoniae, Chlamydia trachomatis, Chlamydia psittaci, Coxiella burnetii, Rickettsial species, Ehrlichia species, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae, Escherichia coli, Vibrio cholerae, Campylobacter species, Neiserria meningitidis, Neiserria gonorrhea, Pseudomonas aeruginosa, other Pseudomonas species, Haemophilus influenzae, Haemophilus ducreyi, other Hemophilus species, Clostridium tetani, other Clostridium species, Yersinia enterolitica, and other Yersinia species, and Mycoplasma species. In one aspect the bacteria is not Bacillus anthracis.

### Claim 11 (depends on 1)

The method of treating a treating, inhibiting, decreasing, reducing, ameliorating, and/or preventing an infectious disease or highly immunosuppressive cancer and/or metastasis in a subject of claim 1, wherein the infectious disease comprises an infection from a fungus selected from the group of fungi consisting of Candida albicans, Cryptococcus neoformans, Histoplasma capsulatum, Aspergillus fumigatus, Coccidiodes immitis, Paracoccidioides brasiliensis, Blastomyces dermitidis, Pneumocystis carinii, Penicillium marneffi, and Alternaria alternata.

### Claim 12 (depends on 1)

The method of treating a treating, inhibiting, decreasing, reducing, ameliorating, and/or preventing an infectious disease or highly immunosuppressive cancer and/or metastasis in a subject of claim 1, wherein the infectious disease comprises a parasitic infection with a parasite selected from the group of parasitic organisms consisting of Toxoplasma gondii, Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae, other Plasmodium species, Entamoeba histolytica, Naegleria fowleri, Rhinosporidium seeberi, Giardia lamblia, Enterobius vermicularis, Enterobius gregorii, Ascaris lumbricoides, Ancylostoma duodenale, Necator americanus, Cryptosporidium spp., Trypanosoma brucei, Trypanosoma cruzi, Leishmania major, other Leishmania species, Diphyllobothrium latum, Hymenolepis nana, Hymenolepis diminuta, Echinococcus granulosus, Echinococcus multilocularis, Echinococcus vogeli, Echinococcus oligarthrus, Diphyllobothrium latum, Clonorchis sinensis; Clonorchis viverrini, Fasciola hepatica, Fasciola gigantica, Dicrocoelium dendriticum, Fasciolopsis buski, Metagonimus yokogawai, Opisthorchis viverrini, Opisthorchis felineus, Clonorchis sinensis, Trichomonas vaginalis, Acanthamoeba species, Schistosoma intercalatum, Schistosoma haematobium, Schistosoma japonicum, Schistosoma mansoni, other Schistosoma species, Trichobilharzia regenti, Trichinella spiralis, Trichinella britovi, Trichinella nelsoni, Trichinella nativa, and Entamoeba histolytica.

### Claim 13 (depends on 1)

The method of treating a treating, inhibiting, decreasing, reducing, ameliorating, and/or preventing an infectious disease or highly immunosuppressive cancer and/or metastasis in a subject of claim 1, wherein cancer is a melanoma.

### Claim 14 (depends on 1)

The method of treating a treating, inhibiting, decreasing, reducing, ameliorating, and/or preventing an infectious disease or highly immunosuppressive cancer and/or metastasis in a subject of claim 1, further comprising detecting whether the cancer is highly immunosuppressive prior to administration of L-fucose.

### Claim 15

A method of decreasing the number of MDSCs in a tumor or infectious microenvironment comprising administering to the subject an agent that increases the amount of fucosylation on myeloid derived suppressor cells (MDSC) and MDSC-like cells.

### Claim 16

A method of increasing the number of dendritic cells in a tumor and/or infectious microenvironment comprising administering to the subject an agent that increases the amount of fucosylation on myeloid derived suppressor cells (MDSC) and MDSC-like cells.
